Fig. 7

Higher levels of circHMGCS1–016 correlated with resistance to anti-PD1 therapy in mice and ICC patients. A. Representative images of the RBE orthotopic ICC tumors from humanized NSG mice (n = 3 /group). B. Tumor growth volume of the RBE orthotopic planted humanized mice from each group (*** p < 0.001, ** p < 0.01); C. The level of GAL-8 in the serum of the RBE orthotopic ICC tumors from each group; Data are representative of 3 independent tests (*** p < 0.001, * p < 0.05, n.s. p > 0.05); D. The level of adenosine concentration in the serum of mice planted with the RBE orthotopic ICC tumors; Data are representative of 3 independent tests(** p < 0.01, * p < 0.05); E. The CD8⁺ and CD4⁺ T cells in the blood of mice planted with the RBE orthotopic ICC tumors (*** p < 0.001); F. At study endpoint, the CD8⁺ and CD4⁺ T cells in IgG and PD-1 treatment group were analyzed by immunohistochemistry (Bar = 200 μm); G. Representative ICC cases from 12 patients who received PD-1 antibody treatment were analyzed by IHC staining for CD8 and circHMGCS1–016 (Bar = 200 μm); H. Twelve patients were divided into two groups according to circHMGCS1–016 expression, and patients in CR, PR, SD, and PD were shown in each group. I. The efficacy of PD1 antibody immunotherapy was assessed by MRI based on RECIST1.1. J. The number of CD8⁺ cells was significantly different between two groups(** p < 0.01)